Natco Pharma shares legal update on Risdiplam patent; stock up 3%
Natco Pharma on Tuesday shared a legal update on the legal proceedings on the Risdiplam compound (used for treating spinal muscular atrophy) launch in India. “The company has received numerous enquiries from investors and patients about the launch, availability and pricing of a generic version of Risdiplam in the Indian market. It wishes to clarify that the Ld. Single Judge of Delhi High Court had through order dated 24.03.2025 denied Roche’s plea for an injunction against the company for the drug. However, (Swiss multinational) Roche has appealed the decision before the Appellate Bench of the Delhi High Court who has currently directed to maintain the status quo. Due to pendency of the proceedings before the court, the company does not…
